< 0.05 level. CONCLUSIONS: The likelihood of refilling an SSRI varies by the specific SSRI and may vary by age, gender, and copayment amount. Patients are more likely to refill the first prescriptions for sertraline or citalopram than for paroxetine.
PMH68 TRENDS IN PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR: 1992-2002
Cooper LM, Zhao Z, Zhu B Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVE: Assess trends in pharmacologic treatment for patients with bipolar disorder. METHODS: A large claims database of insured individuals from October 1992 to September 2002 was analyzed to identify patients diagnosed with bipolar disorder (ICD9-CM: 296.4x-296.8x). Treatment regimens were examined for six-classes of psychotropics (antidepressants, mood-stabilizers, atypical and typical antipsychotics, anxiolytics and hypnotics). RESULTS: Of 13,407 patients, the percent untreated remained stable around 10% over the 10-year period. Among treated patients, about 65% received mood stabilizers and/or antidepressants. The two agents most frequently used were valproate (39.7%) and olanzapine (24.2%) in 2002. Overall, mood stabilizers increased slightly from 59.5% to 64.2%, and atypical antipsychotics increased from 4.5% to 45.1% usage. Antidepressants and anxiolytics remained stable at around 65% and 50% respectively, although the products chosen shifted with new market introductions. Typical antipsychotics decreased from 34.5% to12.4%, and hypnotics decreased from 13.2% to around 7% usage. CONCLUSIONS: Although about two-thirds of patients with bipolar illness receive mood stabilizers, there continues to be opportunity for improvement in pharmacotherapy. It is also important to understand outcomes associated with changing treatment patterns for bipolar patients. 3 ZS Associates, Evanston, IL, USA OBJECTIVE: To examine managed-care treatment patterns for patients diagnosed with bipolar disorder. METHODS: We examined the PharMetrics Integrated Outcomes Database of adjudicated medical and pharmaceutical claims for over 3 million patients from 11 U.S. health plans. We identified 4,455 bipolar patients based on the following criteria: two claims with ICD-9-CM diagnosis for bipolar disorder (296.0, 296.1, 296.4-296.8), age between 10 and 64, and 1 year of continuous eligibility prior to and following the initial bipolar diagnosis with claims beginning January 1, 1999. RESULTS: Of the 4455 bipolar patients, 80% (3555) received medication-based treatment in a 13-month window around the index diagnosis (12 months post and 1 month pre). A total of 38% of bipolar patients used 4 or more medications during the 13 months. On average each patient
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